Omizzur

Executive Summary

Omizzur is a Chinese biotechnology company founded in 2009 and based in Wuhan, specializing in custom peptide synthesis, proteomics services, and peptide-based reagents and diagnostics. The company serves as a critical supplier to research institutions and pharmaceutical companies globally, offering tools for drug discovery and development. In addition to its core service business, Omizzur develops its own diagnostic kits and bioactive peptides for therapeutic applications, positioning itself in both the infectious disease and oncology segments. As a private platform-stage company with 50–200 employees, Omizzur has built a niche in the peptide value chain, though its lack of disclosed funding or valuation makes it a relatively opaque player. Its business model benefits from the growing demand for customized peptides in research and diagnostics, particularly in the Asia-Pacific region. However, the company faces competition from larger contract research organizations and diagnostic firms. Omizzur's ability to scale its proprietary diagnostic products and expand its global customer base will be key to its growth trajectory.

Upcoming Catalysts (preview)

• Q3 2026Launch of new infectious disease diagnostic kit55% success
• Q4 2026Strategic partnership with a major pharmaceutical company for peptide supply40% success
• Q2 2027Expansion into U.S. or European market via distribution agreement30% success